Psyched Wellness Ltd. PSYCF

Company Overview

Psyched Wellness Ltd. (OTCQB: PSYCF; CSE: PSYC) is a Canadian health and wellness company focused on the development and commercialization of products derived from Amanita muscaria, a psychoactive mushroom traditionally used in ethnobotanical practices. The company operates within the emerging functional wellness and nutraceutical sectors, with a strategic emphasis on mushroom-based consumer wellness products intended to support relaxation, mood, and stress management. Psyched Wellness has concentrated much of its commercial activity around its proprietary Amanita muscaria extract known as AME-1, which it markets as a non-psychedelic wellness ingredient after processing intended to reduce ibotenic acid content.

The company’s primary revenue drivers have historically centered on direct-to-consumer wellness product sales and intellectual property development tied to mushroom extraction and formulation processes. Psyched Wellness targets health-conscious consumers in North America seeking alternative wellness supplements and adaptogenic products. The company was founded in 2020 and evolved during a period of heightened investor and consumer interest in psychedelic-adjacent wellness markets. Unlike companies focused on federally controlled psychedelic compounds such as psilocybin or MDMA, Psyched Wellness has positioned itself around legal Amanita muscaria-derived products, giving it a differentiated regulatory and commercial profile in the broader psychedelic wellness industry.

Business Operations

Psyched Wellness primarily operates through a single integrated wellness and consumer products business centered on research, extraction, formulation, and commercialization of Amanita muscaria-derived ingredients and products. Its principal commercial asset is AME-1, a proprietary extract developed for use in tinctures, capsules, and wellness formulations. The company has also developed consumer-facing products under the Calm brand, which has been distributed through e-commerce channels and select retail partnerships. Revenue generation has largely depended on product sales, licensing potential, and continued expansion of its wellness product portfolio.

Operationally, the company’s activities span research and development, regulatory engagement, manufacturing coordination, and consumer marketing. Psyched Wellness has pursued toxicology and safety studies to support marketability and regulatory positioning of AME-1 in North America. While headquartered in Canada, much of its commercial focus has been directed toward the United States wellness market due to its scale and consumer demand for functional mushroom products. Public filings and corporate disclosures indicate reliance on third-party manufacturing and supply-chain relationships rather than vertically integrated production infrastructure.

Strategic Position & Investments

Psyched Wellness has positioned itself within the broader functional mushroom and alternative wellness market by emphasizing legal commercialization pathways for Amanita muscaria-derived products. Its strategy has centered on establishing scientific validation and consumer trust through safety studies, intellectual property development, and brand-building initiatives. The company has publicly highlighted toxicology research and ingredient standardization efforts as core differentiators intended to support long-term retail and regulatory acceptance.

The company’s investments have focused primarily on research, product formulation, regulatory compliance, and commercialization infrastructure rather than large-scale acquisitions. Psyched Wellness has not disclosed major transformative acquisitions comparable to larger publicly traded wellness or pharmaceutical companies. Instead, its strategic direction has emphasized expanding distribution for Calm, increasing awareness of AME-1, and participating in the emerging market for mushroom-derived wellness products. Public disclosures indicate ongoing interest in expanding product formats and strengthening intellectual property protections associated with extraction methodologies and formulation technologies.

Geographic Footprint

Psyched Wellness is headquartered in Toronto, Canada, and operates primarily across North America, with commercial emphasis on the United States consumer wellness market. The company’s securities trade publicly in both Canada and the United States, providing access to cross-border retail investors interested in wellness and psychedelic-adjacent sectors. Its business model relies significantly on e-commerce and digital consumer outreach rather than extensive physical retail infrastructure.

Although the company’s operational footprint remains relatively concentrated compared with multinational wellness companies, its product marketing and investor communications have referenced broader international interest in functional mushrooms and plant-based wellness products. Publicly available disclosures do not indicate substantial direct operating infrastructure outside North America. Data regarding large-scale international subsidiaries or foreign production assets is inconclusive based on available public sources.

Leadership & Governance

Psyched Wellness was co-founded by industry participants involved in early-stage psychedelic and wellness ventures, and the company’s leadership has emphasized regulatory compliance, consumer safety, and scientific validation as central elements of its corporate strategy. Management communications and investor materials consistently frame the company as a consumer wellness enterprise rather than a traditional pharmaceutical developer, with a focus on scalable retail products and legally accessible mushroom-derived ingredients.

Key executives and leaders publicly associated with the company include:

• Jeff Stevens – Chief Executive Officer
• David Shapiro – Chairman
• Brian Tancowny – Chief Financial Officer
• Diana Eberlein – Director
• Jody Aufrichtig – Director

The company’s governance structure follows standard Canadian public-company practices, with oversight responsibilities divided between executive management and the board of directors. Strategic messaging from leadership has consistently emphasized product safety research, consumer education, and expansion within the functional wellness category.